News
Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...
8h
Investor's Business Daily on MSNMerck Plots $10 Billion Takeover Of COPD Drugmaker Verona PharmaMerck said Wednesday it would buy COPD drugmaker Verona Pharma for $10 billion. The news sent Verona stock flying.
15h
Zacks Investment Research on MSNVerona Pharma Stock Jumps 20% on $10B Buyout Offer From MerckVerona Pharma VRNA has signed a definitive agreement with pharma bigwig Merck MRK. Per the terms, the pharma giant will ...
Williams-Sonoma’s first quarter results were met with a negative market reaction, as profit fell short of Wall Street’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results